Search Results

Keywords: epidiolex

Will GW’s multibillion-dollar sale ‘open floodgates’ to pharma-cannabis deal-making?

February 5, 2021 · Updated April 7, 2021

Jazz Pharmaceuticals’ planned $7.2 billion takeover of United Kingdom-based GW Pharmaceuticals could kick off a wave of deal-making between pharma and medical cannabis companies, analysts and industry sources say. But rather than all cannabis producers benefiting, only businesses that have marketable intellectual property and an established foothold in the medical cannabinoid arena will draw serious […]

Read More

GW Pharma expects fiscal 2020 sales to reach $526 million

January 13, 2021 · Updated January 15, 2021

United Kingdom-based GW Pharmaceuticals expects to report annual sales of roughly $526 million for the year ended Dec. 31, 2020, the company said in a preview of its fourth-quarter and full-year results. Fourth-quarter net sales will be approximately $148 million, based on preliminary unaudited financial information, GW said. Epidiolex, the company’s most successful product, accounts […]

Read More

Cannabis firm Canopy Growth sues GW Pharma, claiming patent infringement

December 23, 2020 · Updated April 6, 2021

Canadian cannabis producer Canopy Growth Corp. is suing Britain’s GW Pharmaceuticals in U.S. federal court, alleging that GW is knowingly infringing upon Canopy’s intellectual property. GW uses a Canopy-patented method to extract the CBD that’s the active ingredient in its Epidiolex medication, according to a complaint filed Tuesday in the U.S. District Court for the Western […]

Read More

Insurance-covered medical cannabis reimbursements decline again in Germany

December 17, 2020

Public health insurance reimbursements for cannabis in Germany have fallen for the second straight quarter. Unless this drop is being offset by an increase in private prescriptions, it means that total sales of medical cannabis in Germany – Europe’s largest market – are decreasing. (Data for private prescriptions is not available.) It is the first […]

Read More

Argentina inches closer to first locally made cannabis medicine

November 6, 2020

Argentina might have the first locally-manufactured medical cannabis product as soon as early 2021. An official document shared by local pharmaceutical newspaper Pharmabiz shows that Manuel Limeres, head of Argentina’s National Administration of Drugs, Foods and Medical Devices (ANMAT), authorized the company Laboratorio Alef Medical Argentina to register its Convupidiol product as a medicine. The […]

Read More

Italy backtracks on medical CBD decree

November 2, 2020

The Italian Ministry of Health declined to take action under a decree that would have added certain CBD preparations into the table of medicines in its narcotics law, according to a recent notice in the country’s Official Gazette. On Oct. 1, the decree was approved to pave the way for the authorization of sales of […]

Read More

Newly enforced law might harm Italy’s medical cannabis market, pharmacies warn

October 23, 2020

Italian regulators have reminded pharmacies they are barred from shipping medical cannabis preparations to customers, a major departure from how patients have accessed the medicine for years in the southern European country. Business and patient groups warn that a government crackdown on such shipments – based on a 30-year-old law – could turn back the […]

Read More

WHO cannabis recommendations still face uphill battle for adoption

October 8, 2020 · Updated October 9, 2020

The World Health Organization’s cannabis scheduling recommendations appeared to have limited support at a United Nations Commission on Narcotic Drugs (CND) “intersessional” meeting on Thursday in Vienna. That means the proposals still face an uphill battle ahead of December’s expected vote. As a result, cannabis businesses counting on the adoption of all the WHO recommendations […]

Read More

Spain still won’t allow local cannabis market, even as exports are occurring

October 1, 2020 · Updated October 2, 2020

Spain has several medical cannabis licensed producers, and at least one already exports flower to countries such as Germany. But these products remain unavailable to Spanish patients, and a recent government reply to a member of parliament indicates the situation will not change for the time being. In a reply to a question by Josune […]

Read More

GW Pharmaceuticals cannabis drug gets regulatory OK in Australia

September 24, 2020 · Updated September 25, 2020

GW Pharmaceuticals’ plant-derived CBD drug Epidyolex received approval from Australia’s Therapeutic Goods Administration (TGA) to be used in treating seizures related to Lennox-Gastaut syndrome and Dravet syndrome for patients 2 and older. The approval is the third major global regulatory approval for Epidyolex, GW said in a news release. “The TGA approval is further proof […]

Read More

Insurance-covered medical cannabis falls for the first time in Germany

September 17, 2020

Insurance reimbursements for cannabis in Germany dropped for the first time – on a quarterly basis – since the current medical program started in early 2017, according to new data for the quarter ended June 30, 2020. The reason: Prices fell while the number of prescriptions barely grew. This is consistent with Marijuana Business Daily’s […]

Read More